Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Randomised clinical trial to evaluate ACUITY bleeding rates in ST elevation myocardial infarction (STEMI) patients undergoing rescue percutaneous coronary intervention (PCI) post failed fibrinolysis, treated with bivalirudin or heparin and a glycoprotein IIb/IIIa inhibitor

Next Previous
Trial Profile

Randomised clinical trial to evaluate ACUITY bleeding rates in ST elevation myocardial infarction (STEMI) patients undergoing rescue percutaneous coronary intervention (PCI) post failed fibrinolysis, treated with bivalirudin or heparin and a glycoprotein IIb/IIIa inhibitor

Status: Discontinued
Phase of Trial: Phase IV

Latest Information Update: 18 Nov 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Bivalirudin (Primary) ; Abciximab; Eptifibatide; Heparin; Tirofiban
  • Indications Embolism and thrombosis; Myocardial infarction
  • Focus Adverse reactions
  • Acronyms RESCUE-PCI
  • Sponsors Novartis Pharma A.G.

Most Recent Events

  • 17 Nov 2021 Status changed from completed to discontinued.
  • 08 Jun 2016 Status changed from not yet recruiting to completed.
  • 25 Jul 2011 New trial record

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top